Nevirapine toxicity - Implications for management of South African patients

South African Medical Journal

Volumn 95, Issue 4, 2005, Pages 253-257

  Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANEMIA; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; NAUSEA; NONHUMAN; PREGNANCY; PUBLIC HEALTH SERVICE; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT PLANNING; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 17844404845     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Guay LA, Musoke P, Flemming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
2. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-1092.
3. Fishein J. HIVNET 012 violations of good clinical practice. http://www.honestdoctor.org (last accessed 1 February 2005).
4. The Associated Press-Washington in Depth 13, 14 and 15 December 2004. http://wid.ap.org/nevirapine1.html (last accessed 1 February 2005).
5. Elizabeth Glaser Pediatric AIDS Foundation on issue of prevention of mother-to-child transmission of HIV/AIDS and single dose nevirapine. 14 December 2004. http://www.pedaids.org/ press_release_nevirapine_december_14_2004.html (last accessed 1 February 2005).
6. Project Inform statement regarding the use of single-dose nevirapine to prevent mother-to-child transmission of HIV 15 December 2004. http://www.projectinform.org/newsO4_12nvppr.html (last accessed 1 February 2005).
7. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Press release 17 December 2004. Questions and Answers, The HIVNET 012 study and the safety and effectiveness of nevirapine in preventing mother-to-child transmission of HIV. http://pretoria.usembassy.gov/wwwhpr10w.html (last accessed 1 February 2005).
8. African National Congress Today. 17-23 December 2004, 4(50): 4-8. http://www.anc.org.za/ancdocs/anctoday/2004/text/at5O.txt (last accessed 1 February 2005).
9. Statement by Makerere University, Johns Hopkins University Research Collaboration Investigators, 22 December 2004. http://www.aegis.org/news/2004/MU041201.html (last accessed 1 February 2005).
10. Cohen J. HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy. Science 2004; 306: 2168-2169.
11. Check E. Activists and researchers rally behind AIDS drug for mothers. Nature 2004; 430: 389.
12. Roehr R. Articles criticising nevirapine trial may endanger babies' lives. BMJ 2005; 330: 61-a.
13. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36 (3): 772-776.
14. Jourdain G, Ngo-Giang-Huong N, Le-Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal response to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351 (3): 229-240.
15. FDA Public Health Advisory for Nevirapine (Viramune). 19 January 2005. http://www.fda.gov/cder/drug/advisory/nevirapine.htm (last accessed 1 February 2005).
16. Friis-Moller N, Kirk O, Reis P, et al. Safety of non-nucleoside reverse transcriptase therapy: data from the EuroSIDA study. Abstracts of the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Antivir Ther 2003; 8: L20.
17. Reisler R, Servoss JC, Sherman KE, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials: ACTG Liver Diseases Focus Group. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001. Abstract 43.
18. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers D. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34 (suppl 1), S21-33.
19. Dietrich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38: suppl 2: S80-89.
20. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19(1): 97-99.
21. Allele Frequencies in Worldwide Populations. http://www.allelefrequencies.net (last accessed 1 February 2005).
22. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30(2): 200-215.
23. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and post partum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735.
24. Watts DH, Balasurubramanian R, Maupin RT, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190: 506-516.
25. Lallement M, Jourdain G, Le-Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351(3): 217-228.
26. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected women: a review of the FDA's adverse event reporting system. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, USA. Abstract 944.
27. Antiretroviral pregnancy registry steering committee. Antiretroviral pregnancy registry international interim report for 1 January through 31 July 2004. Wilmington, NC: Registry Coordinating Center. Available from URL. http://www.apregistry.com/forms/report7O4.pdf (last accessed 1 February 2005).
28. British HIV Association Clinical Audit Committee. Oral presentation, British HIV Association Conference, 15-17 April 2004, Cardiff, UK.
29. European Collaboration Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40(1): 258-265.
30. Kramer F, Stek A, Du WB, et al. Nevirapine tolerability in HIV-infected women in pregnancy. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, USA. Abstract 923.
31. Bershoff-Matcha SJ, Mundy LM, Henry JV. Adverse events to nevirapine during pregnancy. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, USA. Abstract 939.
32. Johnson S, Baraboutis JG, Sha BE, Proia LA, Kessler HA. Adverse effects associated with the use of nevirapine in HIV post exposure for 2 health care workers [Letters]. JAMA 2000; 284: 2722.
33. Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposure - Worldwide, 1997-2000. MMWR 2001; 49(51): 1153-1156.
34. Benn PD, Mercey DE, Scott G, Williams IG. Prophylaxis with nevirapine-containing triple regimen after exposure to HIV-1. Lancet 357: 687-688.
35. Rey D, Partisani M, Hess-Kempf G, et al. Tolerance of a short-course of nevirapine, associated with nucleoside analogues, in post exposure prophylaxis of HIV. J Acquir Immune Defic Syndr 2004; 37: 1454-1456.
36. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 36: 1251-1263.